| REVIEW ARTICLE |
|
| Year : 2018 | Volume
: 1
| Issue : 3 | Page : 63-71 |
|
|
The role of integrins in acute leukemias and potential as targets for therapy
Amal A Elsharif, Laurence H Patterson, Steven D Shnyder, Helen M Sheldrake
Institute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of Bradford, Bradford, BD7 1DP, United Kingdom
Correspondence Address:
Dr. Helen M Sheldrake
Institute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of Bradford, Bradford, BD7 1DP
United Kingdom
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/tme.tme_4_19
|
|
|
The interaction between the bone marrow microenvironment and leukemia cells enhances cell adhesion-mediated signals that can promote malignant hematopoietic cell survival and change normal hematopoiesis. Integrins, on the surface of leukemia cells, are involved in this interaction and mediate cell adhesion to integrin receptors of other cells and the extracellular matrix. Studies show that inhibition of several integrins affects leukemia cell migration or survival as well as sensitivity to chemotherapy. This review focuses on the expression and role of key arginine–glycine–aspartate acid (RGD)-binding (αvβ3, α5β1, αIIbβ3) and non-RGD-binding (α2β1, α4β1, α6β1, and αLβ2) integrins on leukemia cells and in the leukemia microenvironment and their potential targeting in leukemia treatment.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
